Infusion systems, infusion devices, and related operating methods are provided. An exemplary method of operating an infusion device capable of delivering fluid to a patient involves obtaining, by a control system associated with the infusion device, an input meal indication, obtaining historical data for the patient associated with the input meal indication, determining an estimated carbohydrate amount corresponding to the input meal indication based at least in part on the historical data, determining a bolus dosage of the insulin based at least in part on the estimated carbohydrate amount, and operating an actuation arrangement of the infusion device to deliver the bolus dosage of the insulin to the patient.

Antibody formulations and methods useful for treatment of patients with AL amyloidosis.

Methods of lowering heart rate during physical activity for a user in need of an increase in their smallest concentric airway cross-sectional area include providing the person with a mandibular repositioning device having a maxillary tooth covering having a driver flange protruding laterally outward on a right and left side proximate a backmost teeth mold and a mandibular tooth covering having a protrusive flange extending cranially therefrom positioned to have a posterior side engaged with the anterior side of each driver flange. The anterior side of each driver flange has a convex curvature, and the posterior side of each protrusive flange has a concave-to-convex curvature from its base toward its most cranial point and a convex portion of the concave-to convex curvature engages the convex curvature of the driver flange in a rest position, and downward movement of the mandibular piece moves the user's mandible forward as well.

Techniques related to temporary setpoint values are disclosed. The techniques may involve causing operation of a fluid delivery device in a closed-loop mode for automatically delivering fluid based on a difference between a first setpoint value and an analyte concentration value during operation of the fluid delivery device in the closed-loop mode. Additionally, the techniques may involve obtaining a second setpoint value. The second setpoint value may be a temporary setpoint value to be used for a period of time to regulate fluid delivery, and the second setpoint value may be greater than the first setpoint value. The techniques may further involve causing operation of the fluid delivery device for automatically reducing fluid delivery for the period of time based on the second setpoint value.

One aspect of the present disclosure relates a method of diagnosis and/or treatment of a solid tumor. The method includes directly measuring neural activity within a solid tumor for a time and determining a state of the solid tumor based on the neural activity. The diagnosis and/or treatment can be determined based on the state of the solid tumor. In some instances, the neural activity can be used in a closed loop to detect the neural activity, determine the state, determine the risk, apply treatment, check again for neural activity, and cease treatment when the neural activity is gone.

In some embodiments, a self-monitoring intravenous catheter system is provided. An alarm controller is provided that receives signals representing a pH value, an oxygen saturation value, and a pressure value in proximity to the distal end of the catheter. By performing a fuzzy logic analysis of the values, the alarm controller is able to detect that the catheter is about to fail or has failed, and can cause alerts to be presented. In some embodiments, an intravenous catheter is provided that has a pH sensor and an oximeter disposed at a distal end of the catheter to obtain the pH value and oxygen saturation values analyzed by the alarm controller. Embodiments of the catheter and self-monitoring intravenous catheter system may be particularly useful in treating neonates, who are sensitive to catheter failure and are not capable of detecting the signs of failure themselves.

Systems and methods are presented for monitoring brain pulsatility. A change in volume of the brain is estimated based at least in part on an output of a non-contact, surface measuring sensor (e.g., a distance sensor or a camera). A metric indicative of brain pulsatility is then calculated based at least in part on a ratio of the estimated change in volume of the brain relative to a change in arterial blood pressure.

A medical treatment system for determining administration of medications to a patient is disclosed. The system uses a plurality of sensors to perform a first set of physiologic measurements in a right side of the heart and a second set of physiologic measurements in a left side of the heart. The system also includes a receiver configured to receive measurement data regarding the first and second sets of physiologic measurements and output to a display device the received measurement data.

Systems, methods, and devices of a health device network may include: a non-invasive glucometer that non-invasively measures analyte levels; an invasive glucometer communicatively coupled directly to the non-invasive glucometer; a cloud-based server communicatively coupled to the non-invasive glucometer or the invasive glucometer; a user device communicatively coupled to the cloud-based server; and/or a user interface that displays the invasive glucose measurement, the non-invasive glucose measurement, a data batch, and/or processed data to the user. The non-invasive glucometer and/or the invasive glucometer may aggregate an invasive glucose measurement and a non-invasive glucose measurement into the data batch. A data analytics application on the cloud-based server may be configured to: integrate the invasive glucose measurement and the non-invasive glucose measurement; identify a correlation between the invasive glucose measurement and the non-invasive glucose measurement; and/or generate a predictive model based on the invasive glucose measurement and the non-invasive glucose measurement.

Systems, methods, and devices of a health device network may include: a non-invasive glucometer that non-invasively measures analyte levels; an invasive glucometer communicatively coupled directly to the non-invasive glucometer; a cloud-based server communicatively coupled to the non-invasive glucometer or the invasive glucometer; a user device communicatively coupled to the cloud-based server; and/or a user interface that displays the invasive glucose measurement, the non-invasive glucose measurement, a data batch, and/or processed data to the user. The non-invasive glucometer and/or the invasive glucometer may aggregate an invasive glucose measurement and a non-invasive glucose measurement into the data batch. A data analytics application on the cloud-based server may be configured to: integrate the invasive glucose measurement and the non-invasive glucose measurement; identify a correlation between the invasive glucose measurement and the non-invasive glucose measurement; and/or generate a predictive model based on the invasive glucose measurement and the non-invasive glucose measurement.